Type 1 diabetes mellitus (T1DM) can be predicted, and immune therapy can alter the progression of the disease. The FDA’s approval of teplizumab as the first disease-modifying therapy for T1DM and the first therapy aimed at delaying the clinical onset of any immune-mediated disease represents a paradigm shift in the treatment of T1DM.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Insel, R. A. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38, 1964–1974 (2015).
Greenbaum, C. J. A key to T1D prevention: screening and monitoring relatives as part of clinical care. Diabetes 70, 1029–1037 (2021).
Bluestone, J. A., Buckner, J. H. & Herold, K. C. Immunotherapy: building a bridge to a cure for type 1 diabetes. Science 373, 510–516 (2021).
Chatenoud, L. & Bluestone, J. A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7, 622–632 (2007).
Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698 (2002).
Keymeulen, B. et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598–2608 (2005).
Sherry, N. et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378, 487–497 (2011).
Aronson, R. et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 37, 2746–2754 (2014).
Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603–613 (2019).
Sims, E. K. et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci. Transl. Med. 13, eabc8980 (2021).
Acknowledgements
The Teplizumab Prevention Trial was conducted by the NIH-funded TrialNet research network. We acknowledge the network research teams and clinical trial participants.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.J.G. and C.S. participate in and receive funding as a clinical site for industry-sponsored or investigator-initiated trials of disease-modifying therapies. In the past 2 years, this has included ProventionBio, Sanofi, BMS, Janssen and Takeda. C.J.G. is a current member of, and previous Chair of, NIH-funded Diabetes TrialNet, which conducted the clinical trial that led to approval. C.S. is also a member of Diabetes TrialNet. C.J.G. is also a member of the NIH-sponsored Immune Tolerance Network, which conducts trials of disease-modifying therapies.
Additional information
Related links
TrialNet: https://www.trialnet.org/
Rights and permissions
About this article
Cite this article
Speake, C., Greenbaum, C.J. Approval of teplizumab: implications for patients. Nat Rev Endocrinol 19, 377–378 (2023). https://doi.org/10.1038/s41574-023-00849-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-023-00849-w